Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22020562 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP1A2CYP2D6KDM4EDRD2 | |
| SCHEMBL12563470 | 0.88 | SMN1; SMN2 (0.34) | ACHE | |
| SCHEMBL26345081 | 0.85 | PIK3CD (0.41) | KDM4ECHRM5ADRA2CACHE | |
| SCHEMBL14277287 | 0.83 | HSD11B1 (0.35) | CYP3A4CYP1A2CYP2D6DRD2DRD3 | |
| SCHEMBL10052290 | 0.83 | CARM1 (0.37) | KDM4EDRD2DRD3CHRM5ADRA2C | |
| SCHEMBL22917561 | 0.82 | CHRM5 (0.33) | CYP3A4CYP1A2CYP2D6KDM4EDRD2 | |
| SCHEMBL18844599 | 0.81 | CHRM5 (0.42) | CYP3A4CYP1A2KDM4ECHRM5ADRA2C | |
| SCHEMBL20227964 | 0.80 | CCR2 (0.34) | CYP3A4CYP1A2CYP2D6DRD2DRD3 | |
| SCHEMBL25786362 | 0.80 | ALDH1A1 (0.37) | CYP2D6KDM4E | |
| SCHEMBL12718204 | 0.79 | BCHE (0.40) | CYP3A4CYP1A2CYP2D6DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024019936-A1 | NANOMATERIALS COMPRISING TRIOLS | BEAM THERAPEUTICS INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023121971-A1 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | BEAM THERAPEUTICS INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121975-A1 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | BEAM THERAPEUTICS INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
| US-9738648-B2 | Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-08-22 | — | — | US | disclosed |
| US-8450494-B2 | Disubstituted benzamide derivatives as glucokinase (GK) activators | CADILA HEALTHCARE LIMITED (IN) | 2013-05-28 | — | — | US | disclosed |
| US-20120149704-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2012-06-14 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2009033084-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | CYP3A4 3931/4885CYP1A2 3111/4885CYP2D6 3259/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | CYP3A4 623/4885CYP1A2 711/4885CYP2D6 669/4885 |
| US-20120149704-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | GCKR, GCK, GK | CYP3A4 239/4885CYP1A2 220/4885CYP2D6 88/4885 |
| US-11225493-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CYP3A4 3931/4885CYP1A2 3111/4885CYP2D6 3259/4885 |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | CYP3A4 3931/4885CYP1A2 3111/4885CYP2D6 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.